Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Last Price: 12.77 - Change: -0.1 - Change %: -0.777
Industry: Drug Manufacturers - Specialty & GenericFollow @stockchartsai on Twitter
In the past 30 trading days, ELAN has been trading in a range between $12.05 and $8.60 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
ELAN is trading below resistance at $12.83, about 0% to the upside. There is support at $11.78 -8% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Elanco Animal Health (ELAN) entered a Green zone 22 days ago on the AI powered stock chart. Wall Street analysts have a recent rating of 3.500, which is a Buy. The current analyst target price is $13.81, which gives it a potential upside of 8.14 % from the recent price of 12.77. The stock is trading 15.04% (potential upside) below its 52 week high of $14.69 and 62.06 % (potential downside) above its 52 week low of $7.88 - based on the recent price.
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.
|Elanco to Participate in Evercore ISI 6th Annual HealthCONx Conference
GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Evercore ISI 6th Annual HealthCONx Conference, November 28-29, 2023. Todd Young, Executive Vice President and CFO, will participate in a fireside chat on Wednesday, November 29 at 8:20 a.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal Health Incorpor.
Source: Business Wire
Mon, 27 Nov 2023 08:00:00 -0500
|Why Elanco Animal Health Stock Was Pure Catnip to Investors This Week
The pet wellness company posted its latest set of quarterly earnings. It beat the consensus analyst estimates for both revenue and profitability.
Source: The Motley Fool
Fri, 10 Nov 2023 17:20:36 -0500
|Elanco Animal Health Incorporated (ELAN) Q3 2023 Earnings Call Transcript
Elanco Animal Health Incorporated (NYSE:ELAN ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Katy Grissom - Head of IR Jeff Simmons - President and CEO Todd Young - CFO Conference Call Participants Michael Ryskin - Bank of America Jon Block - Stifel Erin Wright - Morgan Stanley Chris Schott - JPMorgan Umer Raffat - Evercore ISI Nathan Rich - Goldman Sachs Brandon Vazquez - William Blair Balaji Prasad - Barclays Operator Good morning. My name is Krista, and I'll be your conference operator today.
Source: Seeking Alpha
Tue, 07 Nov 2023 12:08:09 -0500
|Here's What Key Metrics Tell Us About Elanco Animal Health Incorporated (ELAN) Q3 Earnings
While the top- and bottom-line numbers for Elanco Animal Health Incorporated (ELAN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Source: Zacks Investment Research
Tue, 07 Nov 2023 10:31:10 -0500
|Elanco Animal Health Reports Third Quarter 2023 Results
GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2023, provided guidance for the fourth quarter of 2023, and updated guidance for the full year 2023. “Elanco delivered a strong third quarter across both pet health and farm animal, with revenue, adjusted EBITDA, and adjusted EPS growth. Constant currency revenue growth of 5 percent was driven by accelerating contribution from innovation, stabilizing core v.
Source: Business Wire
Tue, 07 Nov 2023 06:33:00 -0500
Stock Analyzed Each Night
Easily Upload Track Your Stocks
See Lists of Stocks Starting New Trends
The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.